EE200100666A - Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil - Google Patents

Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil

Info

Publication number: EE200100666A
Authority: EE; Estonia
Prior art keywords: protein aggregation; amyloid; inhibiting; isoindoline derivatives; imaging diagnostics
Prior art date: 1999-06-10

Application number

EEP200100666A

Other languages

English (en)

Estonian (et)

Inventor

Elizabeth Augelli-Szafran Corinne

Lai Yingjie

Theresa Sakkab Annette

Craswell Walker Lary

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-10

Filing date

2000-05-31

Publication date

2003-02-17

2000-05-31 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

2003-02-17 Publication of EE200100666A publication Critical patent/EE200100666A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Optics & Photonics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Radiology & Medical Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EEP200100666A 1999-06-10 2000-05-31 Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil EE200100666A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13854399P	1999-06-10	1999-06-10
PCT/US2000/015073 WO2000076969A1 (en)	1999-06-10	2000-05-31	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (1)

Publication Number	Publication Date
EE200100666A true EE200100666A (et)	2003-02-17

Family

ID=22482508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100666A EE200100666A (et)	1999-06-10	2000-05-31	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil

Country Status (38)

Country	Link
EP (1)	EP1192131B1 (xx)
JP (1)	JP2003502313A (xx)
KR (1)	KR20020012266A (xx)
CN (1)	CN1156445C (xx)
AP (1)	AP1398A (xx)
AT (1)	ATE272623T1 (xx)
AU (1)	AU777747B2 (xx)
BG (1)	BG106291A (xx)
BR (1)	BR0011446A (xx)
CA (1)	CA2373394A1 (xx)
CR (1)	CR6530A (xx)
CZ (1)	CZ20014366A3 (xx)
DE (1)	DE60012742T2 (xx)
DK (1)	DK1192131T3 (xx)
DZ (1)	DZ3262A1 (xx)
EA (1)	EA004405B1 (xx)
EE (1)	EE200100666A (xx)
ES (1)	ES2223531T3 (xx)
GE (1)	GEP20043407B (xx)
HK (1)	HK1046283B (xx)
HR (1)	HRP20020027A2 (xx)
HU (1)	HUP0201586A2 (xx)
IL (1)	IL146455A0 (xx)
IS (1)	IS6162A (xx)
MA (1)	MA26807A1 (xx)
MX (1)	MXPA01011112A (xx)
NO (1)	NO20015992L (xx)
NZ (1)	NZ515619A (xx)
OA (1)	OA11958A (xx)
PL (1)	PL352294A1 (xx)
PT (1)	PT1192131E (xx)
SI (1)	SI1192131T1 (xx)
SK (1)	SK17622001A3 (xx)
TR (1)	TR200200257T2 (xx)
UA (1)	UA64842C2 (xx)
WO (1)	WO2000076969A1 (xx)
YU (1)	YU86801A (xx)
ZA (1)	ZA200109164B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK17632001A3 (sk) *	1999-06-10	2003-03-04	Warner-Lambert Company	Liečivo na liečbu Alzheimerovej choroby, inhibíciu agregácie amyloidového proteínu a spôsob na zobrazenie depozít amyloidu
US6972287B1 (en)	1999-06-10	2005-12-06	Pfizer Inc.	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
PE20020394A1 (es)	2000-08-18	2002-06-21	Agouron Pharma	Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) *	2000-09-29	2002-03-29	Warner-Lambert Company	Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Napthalene derivatives
PE20040844A1 (es) *	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB2404855A (en) *	2003-07-07	2005-02-16	Pantherix Ltd	Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es)	2006-06-26	2008-09-10	Novartis Ag	Derivados de acido fenilacetico
EP2108644B1 (en) *	2006-11-24	2016-07-20	AC Immune S.A.	N-(Methyl)-pyridin-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins
CA2676715A1 (en)	2007-02-12	2008-08-21	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
ES2862923T3 (es) *	2008-06-09	2021-10-08	Univ Muenchen Ludwig Maximilians	Nuevos fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
AP2011005779A0 (en)	2009-02-06	2011-08-31	Ortho Mcneil Janssen Pharm	Novel susbstituted bicyclic heterocyclic compoundsas gamma secretase modulators.
TWI461425B (zh)	2009-02-19	2014-11-21	Janssen Pharmaceuticals Inc	作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
EP2427453B1 (en)	2009-05-07	2013-07-17	Janssen Pharmaceuticals, Inc.	Substituted indazole and aza-indazole derivatives as gamma secretase modulators
BR112012000915A2 (pt)	2009-07-15	2019-09-24	Janssen Pharmaceuticals Inc	derivados de triazol e imidazol substituídos como moduladores de gama secretase.
EP2523955B1 (en)	2010-01-15	2014-07-16	Janssen Pharmaceuticals, Inc.	Novel substituted bicyclic triazole derivatives as gamma secretase modulators
JP2014508794A (ja)	2011-03-24	2014-04-10	ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド	γ−セクレターゼ調節剤としての新規な置換トリアゾリルピペラジンおよびトリアゾリルピペラジン誘導体
AU2012285931B2 (en)	2011-07-15	2017-01-12	Cellzome Limited	Novel substituted indole derivatives as gamma secretase modulators
CN104583208B (zh)	2012-05-16	2016-09-28	杨森制药公司	可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
WO2014096212A1 (en)	2012-12-20	2014-06-26	Janssen Pharmaceutica Nv	NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
KR102171710B1 (ko)	2013-01-17	2020-10-30	얀센 파마슈티카 엔.브이.	감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
US10562897B2 (en)	2014-01-16	2020-02-18	Janssen Pharmaceutica Nv	Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
ES2838625T3 (es) *	2014-04-14	2021-07-02	Shanghai hengrui pharmaceutical co ltd	Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos
JP2017527559A (ja) *	2014-08-29	2017-09-21	シーエイチディーアイファウンデーション，インコーポレーテッド	ハンチントンタンパク質のイメージング用プローブ
KR102336926B1 (ko)	2014-10-06	2021-12-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제
EP3436446B1 (en)	2016-03-31	2023-06-07	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
UA124708C2 (uk)	2016-09-30	2021-11-03	Вертекс Фармасьютікалз Інкорпорейтед	Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора
AU2017371200B2 (en)	2016-12-09	2021-05-06	Vertex Pharmaceuticals Incorporated	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018140186A1 (en) *	2017-01-28	2018-08-02	Kingchem Life Science Llc	A process for preparing 5-phenoxy-1(3h)isobenzofuranone
MA54105A (fr)	2017-06-08	2021-09-15	Vertex Pharma	Méthodes de traitement de la fibrose kystique
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
KR102606188B1 (ko)	2017-08-02	2023-11-23	버텍스 파마슈티칼스 인코포레이티드	피롤리딘 화합물을 제조하기 위한 공정
CN109232533A (zh) *	2017-09-28	2019-01-18	北京越之康泰生物医药科技有限公司	氮杂环类衍生物、其制备方法及其医药用途
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
US11465985B2 (en)	2017-12-08	2022-10-11	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en)	2018-04-13	2022-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2022306297A1 (en)	2021-07-09	2024-02-08	Plexium, Inc.	Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552426A (en) *	1994-04-29	1996-09-03	Eli Lilly And Company	Methods for treating a physiological disorder associated with β-amyloid peptide

2000
- 2000-05-31 EA EA200101133A patent/EA004405B1/ru not_active IP Right Cessation
- 2000-05-31 BR BR0011446-4A patent/BR0011446A/pt not_active IP Right Cessation
- 2000-05-31 HK HK02107877.1A patent/HK1046283B/zh not_active IP Right Cessation
- 2000-05-31 AU AU53120/00A patent/AU777747B2/en not_active Ceased
- 2000-05-31 WO PCT/US2000/015073 patent/WO2000076969A1/en not_active Ceased
- 2000-05-31 DZ DZ003262A patent/DZ3262A1/fr active
- 2000-05-31 AT AT00938023T patent/ATE272623T1/de not_active IP Right Cessation
- 2000-05-31 UA UA2001117664A patent/UA64842C2/uk unknown
- 2000-05-31 OA OA1200100320A patent/OA11958A/en unknown
- 2000-05-31 IL IL14645500A patent/IL146455A0/xx unknown
- 2000-05-31 DK DK00938023T patent/DK1192131T3/da active
- 2000-05-31 HR HR20020027A patent/HRP20020027A2/hr not_active Application Discontinuation
- 2000-05-31 EE EEP200100666A patent/EE200100666A/xx unknown
- 2000-05-31 CN CNB008087288A patent/CN1156445C/zh not_active Expired - Fee Related
- 2000-05-31 EP EP00938023A patent/EP1192131B1/en not_active Expired - Lifetime
- 2000-05-31 SK SK1762-2001A patent/SK17622001A3/sk unknown
- 2000-05-31 JP JP2001503829A patent/JP2003502313A/ja active Pending
- 2000-05-31 MX MXPA01011112A patent/MXPA01011112A/es not_active Application Discontinuation
- 2000-05-31 PL PL00352294A patent/PL352294A1/xx not_active Application Discontinuation
- 2000-05-31 CZ CZ20014366A patent/CZ20014366A3/cs unknown
- 2000-05-31 CA CA002373394A patent/CA2373394A1/en not_active Abandoned
- 2000-05-31 NZ NZ515619A patent/NZ515619A/en unknown
- 2000-05-31 YU YU86801A patent/YU86801A/sh unknown
- 2000-05-31 GE GE4625A patent/GEP20043407B/en unknown
- 2000-05-31 ES ES00938023T patent/ES2223531T3/es not_active Expired - Lifetime
- 2000-05-31 HU HU0201586A patent/HUP0201586A2/hu unknown
- 2000-05-31 SI SI200030475T patent/SI1192131T1/xx unknown
- 2000-05-31 DE DE2000612742 patent/DE60012742T2/de not_active Expired - Fee Related
- 2000-05-31 AP APAP/P/2002/002389A patent/AP1398A/en active
- 2000-05-31 TR TR2002/00257T patent/TR200200257T2/xx unknown
- 2000-05-31 KR KR1020017015827A patent/KR20020012266A/ko not_active Withdrawn
- 2000-05-31 PT PT00938023T patent/PT1192131E/pt unknown
2001
- 2001-11-06 ZA ZA200109164A patent/ZA200109164B/en unknown
- 2001-11-15 IS IS6162A patent/IS6162A/is unknown
- 2001-12-07 NO NO20015992A patent/NO20015992L/no not_active Application Discontinuation
- 2001-12-07 CR CR6530A patent/CR6530A/es not_active Application Discontinuation
2002
- 2002-01-03 MA MA26467A patent/MA26807A1/fr unknown
- 2002-01-09 BG BG106291A patent/BG106291A/bg unknown

Also Published As

Publication number	Publication date
JP2003502313A (ja)	2003-01-21
AP2002002389A0 (en)	2002-03-31
MXPA01011112A (es)	2002-06-04
CR6530A (es)	2004-03-24
IL146455A0 (en)	2002-07-25
HK1046283B (zh)	2005-01-07
OA11958A (en)	2006-04-13
HUP0201586A2 (en)	2002-08-28
DE60012742T2 (de)	2005-01-13
PL352294A1 (en)	2003-08-11
TR200200257T2 (tr)	2002-06-21
PT1192131E (pt)	2004-11-30
AU5312000A (en)	2001-01-02
AU777747B2 (en)	2004-10-28
NO20015992D0 (no)	2001-12-07
EP1192131B1 (en)	2004-08-04
EA200101133A1 (ru)	2002-06-27
ZA200109164B (en)	2003-02-06
CN1355790A (zh)	2002-06-26
DE60012742D1 (de)	2004-09-09
NZ515619A (en)	2003-05-30
DZ3262A1 (fr)	2000-12-12
GEP20043407B (en)	2004-05-10
EP1192131A1 (en)	2002-04-03
CA2373394A1 (en)	2000-12-21
HRP20020027A2 (en)	2005-02-28
WO2000076969A1 (en)	2000-12-21
ES2223531T3 (es)	2005-03-01
KR20020012266A (ko)	2002-02-15
UA64842C2 (uk)	2004-03-15
MA26807A1 (fr)	2004-12-20
BR0011446A (pt)	2002-03-19
NO20015992L (no)	2002-02-06
ATE272623T1 (de)	2004-08-15
SK17622001A3 (sk)	2003-06-03
CN1156445C (zh)	2004-07-07
IS6162A (is)	2001-11-15
AP1398A (en)	2005-04-21
BG106291A (bg)	2002-05-31
SI1192131T1 (en)	2004-12-31
CZ20014366A3 (cs)	2002-11-13
DK1192131T3 (da)	2004-12-13
HK1046283A1 (en)	2003-01-03
YU86801A (sh)	2004-07-15
EA004405B1 (ru)	2004-04-29

Publication	Publication Date	Title
EE200100666A (et)	2003-02-17	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks isoindoliini derivaatide abil
NO20003251D0 (no)	2000-06-22	Metode for magnetisk resonans avbildning
DE60217090D1 (de)	2007-02-08	Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
EP1171032A4 (en)	2008-10-29	PROCESS FOR IN VIVO IMAGING BY MAGNETIC RESONANCE
EE200100673A (et)	2003-02-17	Meetod amüloidvalgu agregatsiooni inhibeerimiseksja amüloiddeposiitide piltdiagnostika läbiviimiseks
DE60029499D1 (de)	2006-09-07	Toner und Bildherstellungsverfahren
DE60204932D1 (de)	2005-08-11	Toner und Bildaufzeichnungsmethode
EE200200183A (et)	2003-06-16	Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
NO20023333D0 (no)	2002-07-10	Fremgangsmåte for bildefokusering og apparat for avbildning av borehullsresistivitet
FI970388A7 (fi)	1998-07-31	Menetelmä kuvasekvenssien kontrastin parantamiseksi
DE60030355D1 (de)	2006-10-12	Toner und Bildherstellungsverfahren
ATE275145T1 (de)	2004-09-15	Chinazolinderivate zur behandlung von tumoren
NO20022826D0 (no)	2002-06-13	Fremgangsmåte og apparat for forbedring av den vertikale opplösningen av NMR-logger
IT1302195B1 (it)	2000-07-31	Metodo e apparato per filtraggio di coerenza di immagini ultrasoniche.
DE60015555D1 (de)	2004-12-09	Abbildungsmethode mittels thermischem resonanz
NO20002517L (no)	2000-07-14	Magnetisk resonansavbildningsmidler for deteksjon av fysiologiske midler
EE04234B1 (et)	2004-02-16	L-fenüülefriinvesinikkloriidi valmistamise meetod
NO990523D0 (no)	1999-02-04	FremgangsmÕte for fremstilling av kontrastmidler for magnetresonanstomografi
NO20004561D0 (no)	2000-09-13	Metode for magnetisk resonansavbildning
DE69933911D1 (de)	2006-12-21	Phasenempfindliches Inversions-Rückstellungsverfahren der Magnetresonanzbildgebung
FI20021402L (fi)	2003-02-08	Menetelmä magneettiresonanssimittauksen kuvauksen homogenisoimiseksi
FR2838195B1 (fr)	2005-03-18	Procede d'imagerie rapide par resonnance magnetique nucleaire
NO20022157D0 (no)	2002-05-06	Fremgangsmåte for behandling av medikamentavhengighet
SI1080076T1 (sl)	2004-04-30	Izboljšan postopek za pripravo farmacevtsko pomembnih norbenzomorfanskih derivatov
NO20005080D0 (no)	2000-10-09	FremgangsmÕte og anordning for maskinell oppdeling av flatfisk i porsjonsstykker